Day One Biopharmaceuticals Inc (NASDAQ: DAWN) open the trading on Wednesday, with a bit cautious approach as it glided -9.87% to $6.30, before settling in for the price of $6.99 at the close. Taking a more long-term approach, DAWN posted a 52-week range of $6.41-$17.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -38.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -33.82%. This publicly-traded company’s shares outstanding now amounts to $101.35 million, simultaneously with a float of $74.28 million. The organization now has a market capitalization sitting at $638.53 million. At the time of writing, stock’s 50-day Moving Average stood at $7.92, while the 200-day Moving Average is $12.17.
Day One Biopharmaceuticals Inc (DAWN) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Day One Biopharmaceuticals Inc’s current insider ownership accounts for 26.71%, in contrast to 82.40% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s COO, CFO AND SECRETARY sold 4,370 shares at the rate of 11.96, making the entire transaction reach 52,278 in total value, affecting insider ownership by 252,638. Preceding that transaction, on Feb 18 ’25, Company’s GENERAL COUNSEL sold 4,646 for 11.96, making the whole transaction’s value amount to 55,580. This particular insider is now the holder of 39,602 in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
Day One Biopharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -33.82% and is forecasted to reach -0.80 in the upcoming year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Let’s observe the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). It’s Quick Ratio in the last reported quarter now stands at 10.55. The Stock has managed to achieve an average true range (ATR) of 0.53. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.94.
In the same vein, DAWN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.67, a figure that is expected to reach -0.35 in the next quarter, and analysts are predicting that it will be -0.80 at the market close of one year from today.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
[Day One Biopharmaceuticals Inc, DAWN] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 7.75% While, its Average True Range was 0.54.
Raw Stochastic average of Day One Biopharmaceuticals Inc (DAWN) in the period of the previous 100 days is set at 0.55%, which indicates a major fall in contrast to 2.19% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 70.42% that was higher than 65.75% volatility it exhibited in the past 100-days period.
